Summary of minutes of EUCAST Steering Committee Meeting
Malmö, Sweden 7-8 September 2015

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Chairperson Spain
Prof Luc Dubreuil LD CA-SFM France
Dr Christian Giske CG SRGA Sweden
Prof Gunnar Kahlmeter GK Clinical Data Co-ordinator Sweden
Dr P. Christoffer Lindemann CL NWGA Norway
Dr Robin Howe RH BSAC United Kingdom
Prof Johan W. Mouton JM CRG The Netherlands
Prof Sören Gatermann SG German NAC Germany
Dr Iztok Štrumbelj IS EUCAST General Committee Slovenia
Prof Jan Verhagen JV EUCAST General Committee Belgium

Apologies
Prof Alasdair P. MacGowan AM BSAC United Kingdom

Visiting member
Prof Ron Jones RJ USCAST USA

1 Chairman’s welcome

2 Minutes of meeting of 13-14 July 2015 With minor corrections the minutes were accepted.

3 Matters arising from minutes of 13-14 July 2015 (items not covered by agenda) None.

4 New agents Minutes of meetings with companies were accepted for cadazolid (with minor changes) and ceftazidime-avibactam. Ceftolozane-tazobactam breakpoints have been finalised. Discussions continued on possible changes to ceftaroline breakpoints.

5 EUCAST rationale documents The ceftobiprole document is to be completed. The telavancin, dalbavancin, oritavancin and tedizolid documents are being drafted. Ampicillin, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole documents will be released when the format has been updated. Macrolide documents are yet to be completed.

6 Subcommittees
Antifungal susceptibility testing (AFST): Breakpoints for isavuconazole have been set. Discussions on QC for antifungal agents are in progress.
Whole genome sequencing (WGS): Work is in progress.
VetCAST: MIC distributions from different countries are being collected.
MIC distributions and ECOFFs: The remit has been agreed and proposed members will be invited to participate.

7 Breakpoint issues
Breakpoint tables version 6.0: A draft was reviewed.
Definition of the intermediate category: A draft revised definition will be released for consultation.
Bedaquiline MIC determination and QC data: A QC report has been received.
Susceptibility testing of N. gonorrhoeae: The implications of the absence of an EUCAST disk diffusion method were discussed. A EUCAST guidance document on antimicrobial susceptibility testing of N. gonorrhoeae is to be drafted.
Colistin breakpoints: A draft consultation document on colistin breakpoints was discussed and comments sent to the joint EUCAST-CLSI working party.
Review of carbapenem breakpoints: Proposals for breakpoint changes are being discussed.
Expert rules review: Draft updated intrinsic resistance and exceptional phenotype tables were reviewed. The tables will be released for consultation.

Guidelines for manufacturers on data required for new antimycobacterial agents: A report on the EUCAST-ESGMYC meeting in Basel on 16-17 November 2014 will be released on the website.

Daptomycin breakpoints for enterococci: A guidance document giving the background for the “IE” designation is in preparation.

Tigecycline breakpoints for Enterobacteriaceae: A review of breakpoints for Enterobacteriaceae is continuing.

Nitrooxine breakpoints: A consultation document will be released for wide consultation.

Spiramycin breakpoints: Development of breakpoints will not be pursued at present as data required for breakpoint setting are not available.

Temocillin breakpoints: Breakpoints will be developed in 2016.

Agents without breakpoints: A list of antimicrobial agents with indication of whether EUCAST breakpoints are available, and if not the reason for the omission, is being developed.

Review of fluoroquinolone breakpoints: Outstanding issues are being resolved following a review of breakpoints.

Coagulase-negative staphylococci and oxacillin: In breakpoint tables it will be noted that the comment that the presence of the mecA gene correlates with an MIC >0.25 mg/L for coagulase-negative staphylococci excludes S. lugdunensis and S. saprophyticus.

Amoxicillin-clavulanic acid breakpoints for S. pneumoniae: The absence of PK-PD data for amoxicillin-clavulanic acid was highlighted.

Ceftaroline disk diffusion tests: Disk diffusion test issues with S. aureus were discussed.

Organisms without EUCAST breakpoints MICs of trimethoprim-sulfamethoxazole and cephalosporins for Aerococcus spp are being determined by agar dilution in an attempt to overcome problems with broth microdilution. A guidance note on how laboratories should deal with isolates of organisms without breakpoints is being drafted.

EUCAST methods The status of various projects at the EUCAST Development Laboratory was reviewed. Preparation of a WHO video on the disk diffusion method is in progress. A Legionella pneumophila susceptibility testing guidance document will be prepared.

Implementation of EUCAST breakpoints Implementation of EUCAST breakpoints in South American countries was discussed.

EUCAST websites A separate section with all open consultations and responses is to be set up. Some website usage statistics are to be included on the website. Maps showing update of EUCAST guidelines will be posted on the website. The website is frequently updated. Minor changes are not specifically noted but more significant changes are included in the “changes” table accessed from the home page and major items are included in the “News” section. The format of the first page of the MIC distribution website will be reviewed.

Publications and presentations A leading article on changes in the UK in antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST has been accepted for publication in JAC.

NACs No new information.

EUCAST documents A revised version of SOP 3.0 on revision of breakpoints will be released on the website. A procedure for update of guidelines for the detection of resistance mechanisms and
specific resistances of clinical and/or epidemiological importance was agreed.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td><strong>ESCMID</strong> The programme for the 2016 Postgraduate Educational Course is close to completion.</td>
</tr>
<tr>
<td>16</td>
<td><strong>EMA</strong> Revision of the EMA-EUCAST SOP is still being discussed with companies.</td>
</tr>
<tr>
<td>17</td>
<td><strong>ECDC</strong> The new EUCAST contract is in the final stages of agreement.</td>
</tr>
<tr>
<td>18</td>
<td><strong>CLSI</strong> No new information.</td>
</tr>
<tr>
<td>19</td>
<td><strong>Any other business</strong> Proposed changes to the Steering Committee in 2016 will be submitted to the ESCMID executive for approval. The possible implications for breakpoints of the US 21st century cures act were discussed.</td>
</tr>
</tbody>
</table>

Ratified summary minutes of meeting 7-8 September 2015. Prepared by DB, RC, CG and GK